Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.
New Findings on the Treatment of Renal Cell Carcinoma: Highlights from ASCO 2023
Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.
Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.
Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.
Experts discuss the optimal treatment of patients with renal cell carcinoma and brain, bone, or lung metastases.
EP. 6: Managing Adverse Events in Patients With Advanced RCC Receiving an IO/TKI Combination Regimen
Dr Moshe Ornstein details the adverse events seen with IO/TKI combination regimens in patients with advanced renal cell carcinoma and the best strategies for management.
Moshe Ornstein, MD, reviews the design and efficacy and safety data from the phase 3 CONTACT-03 study in metastatic renal cell carcinoma.
The panel highlights novel agents under investigation for the treatment of clear cell renal cell carcinoma.
Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.
Experts discuss recent data on a triplet combination therapy for patients with advanced non-clear cell renal cell carcinoma.
Robert Motzer, MD, led an expert panel to discuss the phase 3 CONTACT-03 which examined patients with renal cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
FDA Approves Ziftomenib in R/R NPM1-Mutated Acute Myeloid Leukemia
3
Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research
4
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
5
